Sarepta Therapeutics, Inc. (SRPT) Forms $78.43 Double Top; FLOW TRADERS COOPERATIEF U A ORDINARY SH (FLTDF) Shorts Decreased By 2.14%

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Logo

FLOW TRADERS COOPERATIEF U A ORDINARY SH (OTCMKTS:FLTDF) had a decrease of 2.14% in short interest. FLTDF’s SI was 374,300 shares in April as released by FINRA. Its down 2.14% from 382,500 shares previously. It closed at $40.25 lastly. It is down 0.00% since April 24, 2017 and is . It has underperformed by 11.55% the S&P500.

Sarepta Therapeutics, Inc. (SRPT) formed double top with $82.35 target or 5.00% above today’s $78.43 share price. Sarepta Therapeutics, Inc. (SRPT) has $5.10B valuation. The stock increased 0.15% or $0.12 during the last trading session, reaching $78.43. About 97,791 shares traded. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 149.90% since April 24, 2017 and is uptrending. It has outperformed by 138.35% the S&P500.

Among 27 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 21 have Buy rating, 0 Sell and 6 Hold. Therefore 78% are positive. Sarepta Therapeutics has $108 highest and $4 lowest target. $69.84’s average target is -10.95% below currents $78.43 stock price. Sarepta Therapeutics had 113 analyst reports since August 5, 2015 according to SRatingsIntel. The rating was upgraded by Morgan Stanley to “Overweight” on Monday, October 2. The firm has “Outperform” rating given on Friday, October 2 by Wedbush. The rating was maintained by SunTrust with “Buy” on Wednesday, March 7. PiperJaffray upgraded the shares of SRPT in report on Monday, September 19 to “Overweight” rating. The firm earned “Market Perform” rating on Thursday, April 21 by William Blair. The company was downgraded on Wednesday, March 21 by Morgan Stanley. Credit Suisse maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on Wednesday, June 28 with “Buy” rating. Jefferies downgraded the stock to “Underperform” rating in Friday, April 29 report. H.C. Wainwright maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on Monday, March 12 with “Buy” rating. The rating was upgraded by Jefferies to “Hold” on Monday, September 19.

Investors sentiment decreased to 1.22 in Q4 2017. Its down 1.66, from 2.88 in 2017Q3. It turned negative, as 27 investors sold Sarepta Therapeutics, Inc. shares while 67 reduced holdings. 45 funds opened positions while 70 raised stakes. 52.88 million shares or 2.28% more from 51.70 million shares in 2017Q3 were reported. Art Advisors Lc holds 0.07% or 29,900 shares. Tower Research Capital Llc (Trc) owns 61 shares or 0% of their US portfolio. Orbimed Advisors Ltd Liability holds 0.07% or 99,400 shares. Pnc Serv Gru invested in 0.01% or 134,314 shares. Advisory Svcs Ltd Liability Corp owns 0.03% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 5,483 shares. Vanguard holds 0.01% or 5.08M shares. Bancorporation Of Montreal Can has invested 0% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Fisher Asset Mgmt Ltd holds 42,648 shares or 0% of its portfolio. Jane Street Grp Limited reported 0% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Alyeska Gp Lp accumulated 1.05 million shares. Polar Capital Llp accumulated 25,000 shares or 0.01% of the stock. Lord Abbett And Ltd Liability Corp holds 537,274 shares. 334,400 are held by Tekla Capital Management Ltd Llc. Tourbillon Cap Prtn Ltd Partnership stated it has 1.91% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Federated Invsts Pa reported 48,909 shares stake.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Institutional Positions Chart